

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIALS

- Comment: Infected Urine as a Risk Factor
for Postprostatectomy Wound Infection 143
JOHN N. KRIEGER, MD

- Infected Urine and Suprapubic Prostatectomy:
The Urological Equivalent of 'Dirty and Infected' Surgery 145
BRUCE H. HAMORY, MD

ORIGINAL ARTICLES

- Infected Urine as a Risk Factor for Postprostatectomy Wound Infection 147
SANTIAGO RICHTER, MD; RUTH LANG, MD; FRUMA ZUR, PHD; ISRAEL NISSENKORN, MD

- Risk Factors for Nosocomial Bacteremia in a Large Spanish
Teaching Hospital: A Case-Control Study 150
ANTONI TRILLA, MD, PHD; JOSEP M. GATELL, MD, PHD; JOSEP MENSA, MD;
XAVIER LATORRE, MD, PHD; MANUEL ALMELA, MD; ELADIO SORIANO, MD;
MARIA T. JIMENEZ DE ANTA, MD, PHD; JUAN GARCIA SAN MIGUEL, MD, PHD

- Daily Meatal Care for Prevention of Catheter-Associated Bacteriuria:
Results Using Frequent Applications of Polyantibiotic Cream 157
DAVID C. CLASSEN, MD; ROBERT A. LARSEN, MD; JOHN P. BURKE, MD;
DAVID W. ALLING, MD; LANE E. STEVENS, BS

- Application of Multilocus Enzyme Electrophoresis
to Epidemiologic Investigations of *Xanthomonas maltophilia* 163
BARBARA SCHABLE, BS, MARGARITA E. VILLARINO, MD, MPH; MARTIN S. FAVERO, PHD;
J. MICHAEL MILLER, PHD

EMPORIATRICS

- Protecting Travelers from Typhoid Fever 168
NALINI RAO, MD, FACP

STATISTICS FOR HOSPITAL EPIDEMIOLOGY

- Statistical Analysis of Stratified 2 X 2 Tables 173
CHARLES S. DAVIS, PHD

SPECIAL REVIEW

- Nosocomial Transmission and Infection Control Aspects of Parasitic and
Ectoparasitic diseases. Part III. Ectoparasites/Summary and Conclusions 179
LUDWIG A. LETTAU, MD, MPH

READERS' FORUM

- Benzalkonium Chloride Is Still in Use 186
LEIGH G. DONOWITZ, MD

- LETTERS TO THE EDITOR 139

- SHEA NEWSLETTER 189

- BOOK REVIEWS 191

From SmithKline Biologicals



Hepatitis B Vaccine (Recombinant)

Choice of dosing regimens

Alternate 0, 1, 2 month dosing regimen for certain populations*

20 mcg recombinant dose

Helps to ensure immune response in adult patients of all ages

	Engerix-B®	Recombivax HB®†
Adult dose (mcg)	20	10
Standard dosing regimen (0, 1 and 6 months)	✓	✓
Alternate 0, 1, 2 month dosing regimen for certain populations*	✓	
Published efficacy data: Neonates born of 'infected mothers'	✓	✓
VACTRAC™-computer software for vaccination tracking and compliance	✓	
Bar-coded, unit-dose vials	✓	

Protection Against Hepatitis B

Lowest Cost Per Dose


Extensively tested and well tolerated[†]

State-of-the-art recombinant technology

14 million doses distributed in over 87 countries[‡]

Switch to Engerix-B

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine^{3,4}



[†]Hepatitis B Vaccine (Recombinant), MSD.

[‡]Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beecham, 1990

Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SmithKline Beecham Pharmaceuticals literature or PDR. The following is a brief summary.

INDICATIONS AND USAGE: 'Engerix-B' is indicated for immunization against infection caused by all known sub-type of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus.

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

WARNINGS: Do not give additional injections to patients experiencing hypersensitivity after an 'Engerix-B' injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

PRECAUTIONS: General: As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection.

Pregnancy: Pregnancy Category C: Animal reproduction studies have not been conducted with 'Engerix-B'. It is also not known whether 'Engerix-B' can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give 'Engerix-B' to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether 'Engerix-B' is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving 'Engerix-B' to a nursing woman.

Pediatric Use: 'Engerix-B' has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine.

ADVERSE REACTIONS: 'Engerix-B' is generally well tolerated. During clinical studies involving over 10,030 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,262 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix-B' and plasmaderived vaccines. In 36 clinical studies a total of 13,495 doses of 'Engerix-B' were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of 'Engerix-B'. Using a symptom checklist, the most frequently reported adverse reactions were injection site soreness (22%), and fatigue (14%). Other reactions are listed below:

Incidence 1% to 19% of Injections: Induration; erythema; swelling; fever ($>37.5^{\circ}\text{C}$); headache; dizziness.

*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

Incidence < 1% of Injections: Pain; pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain/cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of 'Engerix-B' outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia; Guillain-Barré syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

Potential Adverse Experiences: In addition, certain other adverse experiences not observed with 'Engerix-B' have been reported with Heptavax-B*† and/or Recombivax HB*‡. Those listed below are to serve as alerting information to physicians: Optic neuritis.

HOW SUPPLIED: 20 mcg/mL in Single-Dose Vials in packages of 1, 10 and 25 vials.

NDC 5916086041 (package of 1)
NDC 58160-860-11 (package of 10)
NDC 58160-860-16 (package of 25)

10 mcg/0.5 mL in Single-Dose Vials in packages of 1 vial.
NDC 58160-859-01 (package of 1)

†plasma-derived, Hepatitis B Vaccine, MSD.

‡yeast-derived, Hepatitis B Vaccine, MSD.

Manufactured by SmithKline □ Iloalcal, Rixensart, Belgium

Distributed by SmithKline □ eecham Pharmaceuticals, Philadelphia, PA 19101

Date of issuance Sept. 1990

BRS-EB:LBA

©SmithKline Beecham, 1990

Engerix-B is a registered trademark of SmithKline Beecham.

References:

1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281.
2. Based on Medi-Span® Hospital Formulary Pricing Guide, December 1990.
3. Data on file, SmithKline Beecham Pharmaceuticals.
4. Bush L, Moon-sammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989;10:689.



UNTIL WE FIND
A CURE,
THIS IS THE BEST
MEDICINE.

You know what they say about laughter. About sunshine. And about love.

Thousands of children with neuromuscular diseases know, too — thanks to special summer camps sponsored by the Muscular Dystrophy Association.

Each summer, MDA camps provide a special outdoor world-without-barriers to children disabled by neuromuscular disorders. Despite leg braces and wheelchairs, these children swim and fish. They go boating. They horseback ride. They have cookouts and crafts. And each youngster shares a special friendship with a volunteer counselor who works one-on-one with the child.

Summer camps are just one way MDA serves patients with neuromuscular diseases. The Association also maintains some 230 clinics around the country to provide essential services like diagnosis, medical follow-up, physical therapy and counseling. And MDA provides orthopedic equipment and other aids for daily living, all free of charge to the patient and his family.

MDA receives no government grants or fees for services — its programs are funded entirely by private donations. For thousands of patients with neuromuscular diseases, you can be the best medicine. Please send a tax-deductible contribution today.

MDA®

Muscular Dystrophy Association
Jerry Lewis, National Chairman

To make a donation or request to MDA,
to receive an annual report or to obtain
more information, write to:

Muscular Dystrophy Association,
810 Seventh Avenue, New York, NY 10019.
Or contact your local MDA office.

MDA® is a registered service mark of Muscular Dystrophy Association, Inc.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

CONTENTS

EDITORIALS

- Comment: Infected Urine as a Risk Factor for Postprostatectomy Wound Infection 143

JOHN N. KRIEGER, MD

- Infected Urine and Suprapubic Prostatectomy: The Urological
Equivalent of 'Dirty and Infected' Surgery 145

BRUCE H. HAMORY, MD

ORIGINAL ARTICLES

- Infected Urine as a Risk Factor for Postprostatectomy Wound Infection 147

SANTIAGO RICHTER, MD; Ruth LANG, MD; FRUMA ZUR, PHD; ISRAEL NISSENKORN, MD

- Risk Factors for Nosocomial Bacteremia in a Large Spanish Teaching Hospital:
A Case-Control Study 150

ANTONI Trilla, MD, PHD; JOSEP M. GATELL, MD, PHD; JOSEP MENSA, MD;

XAVIER Latorre, MD, PHD; MANUEL ALMELA, MD; ELADIO SORIANO, MD;

Maria T. JIMENEZ DE ANTA, MD, PHD; JUAN GARCIA SAN MIGUEL, MD, PHD

- Daily Meatal Care for Prevention of Catheter-Associated Bacteriuria: Results
Using Frequent Applications of Polyantibiotic Cream 157

DAVID, C. CLASSEN, MD; ROBERTA. LARSEN, MD; JOHN P. BURKE, MD; DAVID W. ALLING, MD;
LANE E. %-EVENS, BS

- Application of Multilocus Enzyme Electrophoresis to
Epidemiologic Investigations of *Xanthomonas maltophilia* 163

BARBARA SCHABLE, BS; MARGARITA E. VILLARINO, MD, MPH; MARTIN S. FAVERO, PHD;
J. MICHAEL MILLER, PHD

EMPORIATRICS

- Protecting Travelers from Typhoid Fever 168

NALINI RAO, MD, FACP

STATISTICS FOR HOSPITAL EPIDEMIOLOGY

- Statistical Analysis of Stratified 2 x 2 Tables 173

CHARLES S. DAVIS, PHD

SPECIAL REVIEW

- Nosocomial Transmission and Infection Control Aspects of Parasitic and
Ectoparasitic Diseases. Part III. Ectoparasites/Summary and Conclusions 179

LUDWIG A. Lettau, MD, MPH

- LETTERS TO THE EDITOR 139

- READERS' FORUM 186

- SHEA NEWSLETTER 189

- BOOK REVIEWS 191

- CALENDAR OF EVENTS C3

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08060. Telephone: (609) 848-1000.

COPYRIGHT 1991 by The Society for Hospital Epidemiology of America, Inc. and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$70.00; Two years-\$105.00; Three years-\$135.00; Institutional: One year-\$80.00; Two years-\$120.00; Three years-\$160.00. Canada: \$18.00 additional each year; all other countries: \$36.00 additional each year. Single copies of current issues may be obtained for \$8.00, United States and possessions; \$16.00 all other countries.

REPRINTS: All requests to reprint or use material published herein should be addressed to Lester J. Robeson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08060. For reprint orders and prices, contact Fran Micaletti at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$1.50 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Secondclass postage is paid at Thorofare, New Jersey 08060, and additional entry points. **POSTMASTER:** Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08060.

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing and Allied Health Literature, and Nursing Abstracts.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS

Beyond Infection Control:

The New Hospital Epidemiology

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL ADVISORY BOARD

Jacques F. Acar, MD	Paris, France
J. Wesley Alexander, MD	Cincinnati, Ohio
Paul Arnow, MD	Chicago, Illinois
Graham A.J. Ayliffe, MD	Birmingham, United Kingdom
Neil L. Barg, MD	Yakima, Washington
Elizabeth Ann Bolyard, RN, MPH, CIC	Atlanta, Georgia
John M. Boyce, MD	Providence, Rhode Island
Professor Dr. Ilja Braveny	Munich, Federal Republic of Germany
Charles Bryan, MD	Columbia, South Carolina
Christian Brun-Buisson, MD	Creteil, France
Donald E. Craven, MD	Boston, Massachusetts
Sue Crow, MSN, RN, CIC	Shreveport, Louisiana
Franz Daschner, MD	Freiburg, Federal Republic of Germany
Leigh G. Donowitz, MD	Charlottesville, Virginia
Charles E. Edmiston, Jr., PhD	Milwaukee, Wisconsin
Theodore C. Eickhoff, MD	Denver, Colorado
Bruce Farber, MD	Manhasset, New York
Victoria J. Fraser, MD	St. Louis, Missouri
Peter C. Fuchs, MD, PhD	Black Butte, Oregon
Richard A. Garibaldi, MD	Farmington, Connecticut
Velvl Greene, PhD, MPH	Beer Sheva, Israel
Robert Gaynes, MD	Atlanta, Georgia
David W. Gregory, MD	Nashville, Tennessee
David K. Henderson, MD	Bethesda, Maryland
Peter N.R. Heseltine, MD	Los Angeles, California
Karen Hoffmann, RN, CIC, MS	Chapel Hill, North Carolina
Marguerite McMillan Jackson, RN, PhD	San Diego, California
Janine Jagger, MPH, PhD	Charlottesville, Virginia
William R. Jarvis, MD	Atlanta, Georgia
Douglas S. Kernodle, MD	Nashville, Tennessee
Robert H. Latham, MD	Nashville, Tennessee
Lewis B. Lefkowitz, MD	Nashville, Tennessee
Hsieh-Shong Leu, MD, MSc	Taipei, Taiwan
Jack Levy, MD	Brussels, Belgium
Victor Lorian, MD	Bronx, New York
Dennis G. Maki, MD	Madison, Wisconsin
Professor Dr. Walter Marget	Munich, Federal Republic of Germany
William J. Martone, MD	Bethesda, Maryland
Allison McGeer, MD	Toronto, Ontario, Canada
John E. McGowan, Jr., MD	Atlanta, Georgia
Jonathan L. Meakins, MD, DSc	Montreal, Quebec, Canada
Raf Mertens, MD	Brussels, Belgium
Robert R. Muder, MD	Pittsburgh, Pennsylvania
Joseph M. Mylotte, MD, CIC	Buffalo, New York
Lindsay Nicolle, MD	Winnipeg, Manitoba, Canada
Juhani Ojajarvi, MD	Helsinki, Finland
Michael T. Osterholm, PhD, MPH	Minneapolis, Minnesota
Jan Evans Patterson, MD	San Antonio, Texas
Sindy M. Paul, MD	Trenton, New Jersey
Michael A. Pfaller, MD	Iowa City, Iowa
Samuel Ponce de Leon, MD, MSc	Mexico City, Mexico
Isaam Raad, MD	Houston, Texas
Manfred L. Rotter, MD, DipBact	Vienna, Austria
Theodore Sacks, MD	Jerusalem, Israel
William E. Scheckler, MD	Madison, Wisconsin
Kent Sepkowitz, MD	New York City, New York
Denis Spelman, MD	Prahran Victoria, Australia
Michael L. Tapper, MD	New York, New York
Clyde Thornsberry, PhD	Brentwood, Tennessee
Professor Leonid P. Titov	Minsk, Republic of Belarus
Timothy R. Townsend, MD	Millwood, Virginia
Antoni Trilla, MD, PhD	Barcelona, Spain
Professor Wang Shu-Qun	Beijing, People's Republic of China
J. John Weems, Jr., MD	Greenville, South Carolina
Robert A. Weinstein, MD	Chicago, Illinois
Professor Dr. W. Weuffen	Greifswald, Federal Republic of Germany
Sergio B. Wey, MD	São Paulo, Brazil
Rebecca Wurtz, MD	Evanston, Illinois

SLACK Incorporated

6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane

Classified/Recruitment Sales Manager

Michele Burch

"Synergism.."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantially less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temperature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77° F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

* *Journal of Clinical Microbiology*,
November 1985, p. 735 - 739



Sporicidin
INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847